Choosing the right cell line for breast cancer research
By D. Holliday, V. Speirs. Breast Cancer Research, 2011
1,477 citations recorded by the source corpus.
Breast cancer is a complex and heterogeneous disease. Gene expression profiling has contributed significantly to our understanding of this heterogeneity at a molecular level, refining taxonomy based on simple measures such as histological type, tumour grade, lymph node status and the presence of predictive markers like oestrogen receptor and human epidermal growth factor receptor 2 (HER2) to a more sophisticated classification comprising luminal A, luminal B, basal-like, HER2-positive and normal subgroups. In the laboratory, breast cancer is often modelled using established cell lines. In the present review we discuss some of the issues surrounding the use of breast cancer cell lines as experimental models, in light of these revised clinical classifications, and put forward suggestions for improving their use in translational breast cancer research.
Subfields: Cancer Research, Oncology
View Paper: https://www.semanticscholar.org/paper/75994d17772dbf60693d3dfbcdc6c019bf6e6f63
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Oncology
Citations in the corpus
- A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity. (2018, neutral): “The most prevalent humanderived BC models to date are cell lines (Holliday and Speirs, 2011) and patient-derived xenografts (PDX) (Whittle et al., 2015).”
- In Vitro Tumor Models: Advantages, Disadvantages, Variables, and Selecting the Right Platform (2016, methodology): “Cancer cell lines are easy to grow, allow direct comparison of experimental results, and are widely used to study molecular mechanisms of tumor cell biology (Greshock et al., 2007; Holliday and Speirs, 2011).”